Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
10.05
-0.98 (-8.88%)
At close: Jul 3, 2025, 1:00 PM
10.00
-0.05 (-0.50%)
After-hours: Jul 3, 2025, 3:47 PM EDT
Artelo Biosciences Employees
Artelo Biosciences had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,619,167
Market Cap
6.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARTL News
- 5 days ago - Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain - GlobeNewsWire
- 9 days ago - Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing - GlobeNewsWire
- 24 days ago - Artelo Biosciences Announces Reverse Stock Split - GlobeNewsWire
- 4 weeks ago - Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - GlobeNewsWire
- 4 weeks ago - New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression - GlobeNewsWire
- 7 weeks ago - Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - GlobeNewsWire
- 3 months ago - Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - GlobeNewsWire